Overview of GCA Overview of GCA cont Epidemiologic Factors Related to GCA Headache Visual Signs and Symptoms Optic Disc in GCA Vision Loss in GCA Jaw C laudication The PMR Connection Diagnosing GCA ID: 775380
Download Presentation The PPT/PDF document " Giant Cell Arteritis: Timely Diagnosis ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Giant Cell Arteritis: Timely Diagnosis and Emerging Treatment Strategies
Slide2Overview of GCA
Slide3Overview of GCA (cont)
Slide4Epidemiologic Factors Related to GCA
Slide5Headache
Slide6Visual Signs and Symptoms
Slide7Optic Disc in GCA
Slide8Vision Loss in GCA
Slide9Jaw Claudication
Slide10The PMR Connection
Slide11Diagnosing GCA
Slide12Normal TA, 4X, H&E Stain
Slide13Normal TA, 4X, Elastin Stain
Slide14TA, 4X, H&E Stain: Evidence of Arteritis
Slide15TA, 4X, Elastin Stain: Evidence of Arteritis
Slide16Ultrasound: Normal TA, Right Parietal Ramus
Slide17Ultrasound: Normal Right Parietal Ramus
Slide18Ultrasound: Hypoechoic Circumferential Wall Thickening Due to Vasculitic Wall Edema -- Halo Sign
Slide19Ultrasound: Left Mid-Subclavian Artery With Hypoechoic Wall Edema and Halo Sign
Slide20Fused PET CT: Increased FDG Uptake in Ascending and Descending Aorta Walls
Slide21Diagnostic Algorithm for GCA
Slide22Conventional Treatments
Slide23Steroids: Not Effective in Long-Term Disease Control (GiACTA)
Slide24Methotrexate in GCA
Slide25Infliximab in GCA
Slide26New Knowledge on Pathophysiology of GCA
Slide27Emerging Treatments: TCZ
Slide28Relapse-Free Survival After Stopping TCZ
Slide29GiACTA Trial
Slide30Sustained Remission Primary and Key Secondary Endpoints
Slide31Sensitivity Analysis
Slide32Time to First Flare Following Clinical Remission
Slide33Steroid Dosing, Without TCZ
Slide34TCZ Had Significant Steroid-Sparing Effect
Slide35Safety Overview
Slide36IL-12/23 Inhibitor: Ustekinumab
Slide37IL-23 Inhibitor: Ustekinumab (cont)
Slide38Ustekinumab: Conclusions
Slide39Concluding Remarks
Slide40Abbreviations
Slide41Abbreviations (cont)